Vistagen Therapeutics, Inc. (VTGN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Vistagen Therapeutics, Inc. on February 20, 2026, covering events occurring on February 13, 2026. The Company is a biopharmaceutical entity incorporated in Nevada and listed on the Nasdaq Capital Market under the symbol VTGN.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial statements or performance data.
Material Changes
The primary material change reported is the resignation of Paul Edick from the Board of Directors effective February 13, 2026. The Company has confirmed it is actively seeking new candidates to fill the resulting vacancy.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, specific risks, contingencies, or unusual items. The sole focus is the departure of a director.
Key Facts for Investor Verification
- Paul Edick resigned from the Board of Directors on February 13, 2026.
- The Board is currently in the process of recruiting a replacement for the vacancy.
- No financial performance data or strategic updates were included in this specific filing.